SOM Biotech participated in the World Orphan Drug Congress Europe 2019 on November 12th -14th– in Barcelona, Spain, where the company was a Showcase Sponsor.
Raul Insa – CEO of SOM Biotech – presented “Case study: Systematic drug re-innovation and clinical evidence in orphan diseases”. SOM Biotech shared its latest findings in drug discovery and development focused on the high performance of its cutting-edge AI screening platform to accelerate orphan drug development and facilitate patient access to effective medicines.
Santiago Esteva – Clinical Operations Manager, Gal·la Pericot – R&D Manager, Aileen Ferré – Scientist and Gerard Jorba – Scientist- attended the Congress, a platform for participants to meet experts and exchange knowledge into the causes and treatment of orphan diseases.
The World Orphan Drug Congress, is the largest and most established European orphan drug event, where leading biotech and pharma companies, investors, scientists, government authorities and patient advocacy groups meet to address the scientific, the strategic and the commercial aspects of bringing new treatments to patients who suffer from rare diseases.
